AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch

AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.

AstraZeneca PLC has decided to stop INEXAS, the Phase IIa trial to investigate the effects on asthma patients of the inhaled Interferon beta-1a compound AZD9412 in-licensed from Synairgen PLC, because a mid-way analysis showed too few participants reported severe exacerbations, the primary endpoint target, making conclusions difficult.

More from Respiratory

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

2025’s Biggest New Launches

 

Big pharma once again fails to dominate the top 20 expected best sellers from products due for launch this year. Small-to-medium pharma account for nearly half the list, while Vertex has two products in the top five.

Spotlight On IPF Successors To Esbriet And Ofev

 

Only two drugs have been approved for the progressive fibrosing interstitial lung disease but the pipeline is full of promising, and hopefully more tolerable, candidates.

Bridge Biotherapeutics Confident In IPF Contender As It Seeks Global Partner

 
• By 

The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.

More from Therapy Areas

Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round

 

The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.

AstraZeneca’s Oral SERD Is First To Succeed In Frontline Breast Cancer

 

A novel Phase III design using circulating DNA testing has delivered success for SERENA-6, putting it ahead of competing studies from Roche and Pfizer/Arvinas.

Laser Focus Lifts Leo Pharma To Point Of Profitability

 
• By 

CEO Christophe Bourdon tells Scrip that the Danish dermatology specialist is delivering consistently strong sales while maintaining financial discipline and has created the foundation for long-term growth.